Tumor microenvironment induces innate RAF-inhibitor resistance through HGF secretion

The Eli and Edythe L. Broad Institute, 7 Cambridge Center, Cambridge, Massachusetts 02142, USA.
Nature (Impact Factor: 41.46). 07/2012; 487(7408):500-4. DOI: 10.1038/nature11183
Source: PubMed


Drug resistance presents a challenge to the treatment of cancer patients. Many studies have focused on cell-autonomous mechanisms of drug resistance. By contrast, we proposed that the tumour micro-environment confers innate resistance to therapy. Here we developed a co-culture system to systematically assay the ability of 23 stromal cell types to influence the innate resistance of 45 cancer cell lines to 35 anticancer drugs. We found that stroma-mediated resistance is common, particularly to targeted agents. We characterized further the stroma-mediated resistance of BRAF-mutant melanoma to RAF inhibitors because most patients with this type of cancer show some degree of innate resistance. Proteomic analysis showed that stromal cell secretion of hepatocyte growth factor (HGF) resulted in activation of the HGF receptor MET, reactivation of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-OH kinase (PI(3)K)-AKT signalling pathways, and immediate resistance to RAF inhibition. Immunohistochemistry experiments confirmed stromal cell expression of HGF in patients with BRAF-mutant melanoma and showed a significant correlation between HGF expression by stromal cells and innate resistance to RAF inhibitor treatment. Dual inhibition of RAF and either HGF or MET resulted in reversal of drug resistance, suggesting RAF plus HGF or MET inhibitory combination therapy as a potential therapeutic strategy for BRAF-mutant melanoma. A similar resistance mechanism was uncovered in a subset of BRAF-mutant colorectal and glioblastoma cell lines. More generally, this study indicates that the systematic dissection of interactions between tumours and their micro-environment can uncover important mechanisms underlying drug resistance.

Download full-text


Available from: Zhi Rong Qian
  • Source
    • "Up-regulation of receptor tyrosine kinase signaling, or mutations in NRAS or MEK have all been shown to regulate resistance, as have upregulation or alternative splicing of V600E BRAF itself (Lito et al., 2013). Similarly, increased release of growth factors by the stromal cells, or alterations to transcription factors that control expression of signaling components can mediate resistance (Straussman et al., 2012; Wilson et al., 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: BRAF inhibitors can extend progression-free and overall survival in melanoma patients whose tumors harbor mutations in BRAF. However, the majority of patients eventually develop resistance to these drugs. Here we show that BRAF mutant melanoma cells that have developed acquired resistance to BRAF inhibitors display increased oxidative metabolism and increased dependency on mitochondria for survival. Intriguingly, the increased oxidative metabolism is associated with a switch from glucose to glutamine metabolism and an increased dependence on glutamine over glucose for proliferation. We show that the resistant cells are more sensitive to mitochondrial poisons and to inhibitors of glutaminolysis, suggesting that targeting specific metabolic pathways may offer exciting therapeutic opportunities to treat resistant tumors, or to delay emergence of resistance in the first-line setting.
    Full-text · Article · Sep 2015 · Molecular oncology
  • Source
    • "However culturing both cell types separately did not allow for any interaction between the tumour cells and the normal tissue. The direct and paracrine tumour–host interaction has been repeatedly demonstrated to affect chemo (Straussman et al., 2012) and radiosensitivity (Upreti et al., 2011), proliferation (Spink et al., 2006), angiogenesis (Wartenberg, 2001), cell adhesion (Chambers et al., 2011) and gene expression (L Berg et al., 2014). Spheroid co-cultures have been used to demonstrate differential response to local intravesical treatment in bladder cancer (Kilani et al., 2003, 2002). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Physiologically relevant in vitro models can serve as biological analytical platforms for testing novel treatments and drug delivery systems. We describe the first steps in the development of a 3D human brain tumour co-culture model that includes the interplay between normal and tumour tissue along with nutrient gradients, cell-cell and cell-matrix interactions. The human medulloblastoma cell line UW228-3 and human foetal brain tissue were marked with two supravital fluorescent dyes (CDCFDASE, Celltrace Violet) and cultured together in ultra-low attachment 96-well plates to form reproducible single co-culture spheroids (d = 600 μm, CV% = 10%). Spheroids were treated with model cytotoxic drug etoposide (0.3-100 μM) and the viability of normal and tumour tissue quantified separately using flow cytometry and multiphoton microscopy. Etoposide levels of 10 μM were found to maximise toxicity to tumours (6.5% viability) while stem cells maintained a surviving fraction of 40%. The flexible cell marking procedure and high-throughput compatible protocol make this platform highly transferable to other cell types, primary tissues and personalised screening programs. The model's key anticipated use is for screening and assessment of drug delivery strategies to target brain tumours, and is ready for further developments, e.g differentiation of stem cells to a range of cell types and more extensive biological validation
    Full-text · Article · Jan 2015 · Journal of Biotechnology
  • Source
    • "Intratumoral heterogeneity and consequences for targeted therapies tome 102 > n81 > January 2015 melanoma cells with BRAF (V600E) mutation [34], or fibroblastderived PDGF-C was shown to rescue anti-VEGFA treatment in murine lymphomas [35]. Other components of the stroma, like endothelial cells, can also function as suppliers of factors that can fuel resistance to treatment. "
    [Show abstract] [Hide abstract]
    ABSTRACT: According to the clonal model and Darwinian evolution, cancer cell evolves through new mutations helping it to proliferate, migrate, invade and metastasize. Recent genetic studies have clearly shown that tumors, when diagnosed, consist of a large number of mutations distributed in different cells. This heterogeneity translates in substantial genetic plasticity enabling cancer cells to adapt to any hostile environment. As targeted therapy focuses only on one pathway or protein, there will always be a cell with the "right" genetic background to survive the treatment and cause tumor relapse. Because today's targeted therapies never took tumor heterogeneity into account, nearly all novel drugs fail to provide patients with a considerable improvement of the survival. However, emerging proteomic studies guided by the idea that Darwinian selection is governed by the phenotype and not genotype, show that heterogeneity at the protein level is much less complex, then it could be expected from genetic studies. This information together with the recent trend to switch from functional to cytotoxic targeting may offer an entirely new strategy to efficiently combat cancer. Copyright © 2014 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.
    Full-text · Article · Jan 2015 · Bulletin du cancer
Show more